Kiniksa Pharmaceuticals, Ltd. Q3 2025 Earnings Recap

KNSA Q3 2025 October 28, 2025

Get alerts when KNSA reports next quarter

Kiniksa Pharmaceuticals reported strong third-quarter results, with ARCALYST revenue reaching $180.9 million, reflecting significant growth and a revised full-year sales guidance increase.

Earnings Per Share Miss

$0.23 vs $0.33 est.

-30.3% surprise

Revenue Miss

180855000 vs 197094600 est.

-8.2% surprise

Market Reaction

1-Day -2.88%

5-Day -8.84%

30-Day +2.41%

See KNSA alongside your other holdings

Add to your portfolio — free

Key Takeaways

ARCALYST revenue grew by approximately $69 million year-over-year and $24 million sequentially.
Full-year net sales guidance raised to $670 million - $675 million, up from previous guidance of $625 million - $640 million.
KPL-387 received FDA Orphan Drug Designation for recurrent pericarditis, enhancing future growth potential.
New patient enrollments surged, with a total prescriber count exceeding 3,825, indicating strong market penetration and adoption.
The average duration of ARCALYST therapy increased to approximately 32 months, reflecting patient satisfaction and treatment effectiveness.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit KNSA on AllInvestView.